Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | OXTR | P30559 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568657 | 0.91 | NR1I2 (0.65) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL10956866 | 0.90 | NR1I2 (0.64) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL6608045 | 0.87 | MAPT (0.61) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL5283944 | 0.84 | ALDH1A1 (0.71) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL5281910 | 0.82 | NR1I2 (0.55) | NR1I2TSHRPTPN1MAPK1SMN1; SMN2 | |
| SCHEMBL16894172 | 0.82 | POLB (0.70) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL14878119 | 0.82 | NR1I2 (0.57) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL702692 | 0.82 | KEAP1 (0.68) | ALDH1A1KEAP1NFE2L2L3MBTL1 | |
| SCHEMBL25735703 | 0.79 | NR1I2 (0.54) | NR1I2TSHRPTPN1ALDH1A1MAPK1 | |
| SCHEMBL16557448 | 0.78 | POLB (0.58) | NR1I2TSHRALDH1A1SMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | NR1I2 122/4885TSHR 112/4885PTPN1 2875/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | NR1I2 3523/4885TSHR 4292/4885PTPN1 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.